US Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Report: Insights, Trends and Forecast (2021-2031)

US Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Report: Insights, Trends and Forecast (2021-2031)

Nov 2019 Koncept Analytics Pharmaceutical87 Pages Price :
$ 1500

The U.S. OAB market is estimated to reach US$3.49 billion in 2031, growing at a CAGR of 5.01%, for the period spanning from 2021-2031. The factors such as rising ageing population, increasing healthcare expenditure, growing obese population, surging diabetic prevalence, increasing coffee consumption and accelerating economic growth are expected to drive the market growth. However, growth of the industry would be challenged by entry of generic drugs, stringent regulations, associated business risk and side effects of oral therapies. A few notable trends include advancing innovative therapies, rising awareness of overactive bladder, growing adoption of procedural (third line) therapy, development of gene therapy and progressing drug pipeline.

The three main treatment approaches for the treatment of overactive bladder are behavioural therapy (Bladder Training & Pelvic Floor Exercises), prescription therapy (Oral Anticholinergics & ?3 Adrenoreceptor Agonist) and procedural therapy (BOTOX & Neuromodulation).

The fastest growing market is the U.S. owing to continuous advancement in ?3 Adrenoreceptor Agonist drugs, increasing OAB population and growing research & development efforts by domestic pharmaceutical firms to launch novel drugs with innovative mechanism of actions drugs.

Scope of the report:

The report provides a comprehensive analysis of the U.S. OAB market, segmented on the basis of drug class i.e. Anticholinergics and ?3 Adrenoreceptor Agonist and drug type i.e. Vibegron and Mirabegron.
The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
The competitive landscape of the market, along with the company profiles of leading players [Allergan Plc, Pfizer Inc., Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Medtronic Plc and Sumitomo Chemical Co., Ltd. (Urovant Sciences Ltd.)] are also presented in detail.

Key Target Audience:

  • Drug Manufacturers
  • Raw Material Suppliers
  • End Users
  • Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Content

1. Market Overview
1.1 Overactive Bladder
1.2 Symptoms & Diagnosis
1.3 Treatment
1.4 Overactive Bladder with BPH

2. The U.S. Market Analysis
2.1 Overactive Bladder Market
2.1.1 The U.S. Overactive Bladder Market Value Forecast
2.1.2 The U.S. Overactive Bladder Market Value by Drug Class
2.1.3 The U.S. Anticholinergics Market Value Forecast
2.1.4 The U.S. ?3 Adrenoreceptor Agonists Market Value Forecast
2.1.5 The U.S. ?3 Adrenoreceptor Agonists Market Value by Drug Type
2.1.6 The U.S. Vibegron Drug Revenue Forecast
2.1.7 The U.S. Overactive Bladder Patient Population Forecast
2.1.8 The U.S. Overactive Bladder Treated Patient Population Forecast
2.1.9 The U.S. Overactive Bladder Prescriptions Forecast
2.1.10 The U.S. Vibegron Drug Prescriptions Forecast
2.1.11 The U.S. Mirabegron Drug Prescriptions Forecast
2.2 Overactive Bladder Market with BPH
2.2.1 The U.S. Overactive Bladder with BPH Patient Population Forecast
2.2.2 The U.S. ?3 Adrenoreceptor Agonist Market by Penetration Rate
2.2.3 The U.S. ?3 Adrenoreceptor Agonist Patient Penetration by Drug
2.2.4 The U.S. Vibegron Drug Revenue Forecast
2.2.5 The U.S. Vibegron Prescriptions Forecast
2.2.6 The U.S. Mirabegron Prescriptions Forecast

3. Market Dynamics
3.1 Growth Drivers
3.1.1 Rising Ageing Population
3.1.2 Increasing HealthCare Expenditure
3.1.3 Growing Obese Population
3.1.4 Surging Diabetic Prevalence
3.1.5 Increasing Coffee Consumption
3.1.6 Accelerating Economic Growth
3.2 Key Trends and Developments
3.2.1 Advancing Innovative Therapies
3.2.2 Rising Awareness of Overactive Bladder
3.2.3 Growing Adoption of Procedural (Third Line) Therapy
3.2.4 Development of Gene Therapy
3.2.5 Progressing Drug Pipeline
3.3 Challenges
3.3.1 Entry of Generic Drugs
3.3.2 Stringent Regulations
3.3.3 Associated Business Risk
3.3.4 Side Effects of Oral Therapies

4. Competitive Landscape
4.1 Global OAB Market
4.1.1 Key Players – Revenue Comparison
4.1.2 Key Players – Market Cap Comparison
4.1.3 Key Players – Research & Development Expenditure Comparison

5. Company Profiles
5.1 Allergan Plc
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
5.2 Pfizer Inc.
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
5.3 Astellas Pharma Inc.
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
5.4 Hisamitsu Pharmaceutical Co., Inc.
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
5.5 Medtronic Plc
5.5.1 Business Overview
5.5.2 Financial Overview
5.5.3 Business Strategies
5.6 Sumitomo Chemical Co., Ltd. (Urovant Sciences Ltd.)
5.6.1 Business Overview
5.6.2 Financial Overview
5.6.3 Business Strategies

List of Table

Overactive Bladder Drug Pipeline (2019-2023)
Key Players – Revenue Comparison (2018)
Pfizer Inc. Segments Overview
Astellas Pharma Segment Overview
Medtronic Segment Overview
Sumitomo Chemical (Urovant Sciences) Segment Overview

List of Chart

Normal Bladder vs. Overactive Bladder
OAB Treatment Approaches
The U.S. Overactive Bladder Market Value Forecast (2021-2031)
The U.S. Overactive Bladder Market Value by Drug Class (2021/2031)
The U.S. Anticholinergics Market Value Forecast (2021-2031)
The U.S. ?3 Adrenoreceptor Agonists Market Value Forecast (2021-2031)
The U.S. ?3 Adrenoreceptor Agonists Market Value by Drug Type (2021/2031)
The U.S. Vibegron Drug Revenue Forecast (2021-2031)
The U.S. Overactive Bladder Patient Population Forecast (2021-2031)
The U.S. Overactive Bladder Treated Patient Population Forecast (2021-2031)
The U.S. Overactive Bladder Prescriptions Forecast (2021-2031)
The U.S. Vibegron Drug Prescriptions Forecast (2021-2031)
The U.S. Mirabegron Drug Prescriptions Forecast (2021-2031)
The U.S. Overactive Bladder with BPH Patient Population Forecast (2021-2031)
The U.S. ?3 Adrenoreceptor Agonist Market by Penetration Rate (2021-2031)
The U.S. ?3 Adrenoreceptor Agonist Patient Penetration by Drug (2021/2025/2031)
The U.S. Vibegron Drug Revenue Forecast (2021-2031)
The U.S. Vibegron Prescriptions Forecast (2021-2031)
The U.S. Mirabegron Prescriptions Forecast (2021-2031)
The U.S. Ageing Population (2014-2018)
The U.S. HealthCare Expenditure (1990-2020)
The U.S. Obese Population (2014-2018)
The U.S. Diagnosed Diabetic Population (2014-2018)
The U.S. Coffee Consumption Volume (2014-2018)
The U.S. GDP per Capita (2014-2018)
Key Players – Market Cap Comparison (2019)
Key Players – Research & Development Expenditure Comparison (2017-2018)
Allergan Net Revenues and Net Loss (2014-2018)
Allergan Net Revenues by Segments (2018)
Allergan Net Revenues by Region (2018)
Pfizer Revenues and Net Income (2014-2018)
Pfizer Revenues by Segments (2018)
Pfizer Revenues by Region (2018)
Astellas Pharma Revenues and Profit (2015-2019)
Astellas Pharma Revenues by Segment (2019)
Astellas Pharma Revenues by Region (2019)
Hisamitsu Pharma Net Sales and Profit (2015-2019)
Hisamitsu Pharma Net Sales by Segments (2019)
Hisamitsu Pharma Net Sales by Region (2019)
Medtronic Net Sales and Net Income (2015-2019)
Medtronic Net Sales by Segment (2019)
Medtronic Net Sales by Region (2019)
Sumitomo Chemical (Urovant Sciences) Net Sales and Net Income (2015-2019)
Sumitomo Chemical (Urovant Sciences) Net Sales by Segments (2019)

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 1500
$ 2100

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top